Amgen Invests Additional $300 Million in U.S. Manufacturing Network

Amgen will invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.

This investment in Puerto Rico builds on Amgen’s broader U.S. manufacturing expansion strategy. Over the past year, the company has announced planned investments of $650 million in Puerto Rico, $900 million in Ohio and $600 million in a science and innovation center in California. In addition, Amgen has invested more than $1.5 billion in North Carolina.

“Amgen has been a leader in U.S. biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing,” said Robert A. Bradway, Chairman and CEO at Amgen. “By growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs.”

Amgen’s expansion of its biologics manufacturing facility in Puerto Rico will strengthen existing advanced manufacturing roles, support workforce development across the region and generate hundreds of construction jobs. Established in 1992, the company’s Juncos site is one of the largest and most advanced biomanufacturing facilities in the world, producing biologic medicines distributed to more than 60 countries.